ArticlebioRxiv : the preprint server for biology2025
Controlled Delivery of a Neurotrophic Factor in the Adult Mouse Brain Using Engineered Microglia.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Microglia, the resident immune cells of the central nervous system, have been proposed as vehicles for delivering therapeutic biologics. These cells can be genetically engineered in vitro and transplanted into host animals following ablation of endogenous microglia, enabling repopulation of the brain parenchyma. However, current replacement strategies often rely on radiation or transgenic models, limiting their clinical relevance. CSF1R inhibitors offer a more translational approach to microglia ablation, though surviving host cells can compete with transplanted microglia during repopulation. In this study, we successfully ablated endogenous microglia using a CSF1R inhibitor in adult mice and developed a method to transplant engineered microglia expressing Brain-Derived Neurotrophic Factor (BDNF) in a doxycycline-inducible manner. To enhance engraftment, transplanted cells also expressed a constitutively active CSF1R mutant (caCSF1R). BDNF-expressing transplanted microglia spread through large areas of host mice brains, displayed similar morphology and transcriptional profile to repopulating host microglia, and responded to pro-inflammatory stimuli. Treatment with doxycycline resulted in increased BDNF expression and TrkB phosphorylation in the host brain. Expression of caCSF1R provided transplanted cells with a competitive advantage over endogenous repopulating cells, resulting in the accelerated spread of the transplants. Our results demonstrate the functional integration and therapeutic potential of microglia as vehicles for delivering neurotrophic factors to the brain in a controllable manner. Furthermore, we show that caCSF1R expression is able to enhance the spread of transplanted microglia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.